Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.

Aim: To assess the efficacy, safety and tolerability of cotadutide in patients with type 2 diabetes mellitus and chronic kidney disease.

Materials And Methods: In this phase 2a study (NCT03550378), patients with body mass index 25-45 kg/m , estimated glomerular filtration rate 30-59 ml/min/1.73 m and type 2 diabetes [glycated haemoglobin 6.

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.

Context: Cotadutide is a dual receptor agonist with balanced glucagon-like peptide-1 and glucagon activity.

Objective: To evaluate different doses of cotadutide and investigate underlying mechanisms for its glucose-lowering effects.

Design/setting: Randomized, double-blind, phase 2a study conducted in 2 cohorts at 5 clinical trial sites.